Brokerages Set Henry Schein, Inc. (NASDAQ:HSIC) Target Price at $80.10

Henry Schein, Inc. (NASDAQ:HSIC) has received a consensus rating of “Moderate Buy” from the twelve research firms that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $80.10.

HSIC has been the subject of a number of recent analyst reports. Mizuho assumed coverage on shares of Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price objective for the company. Jefferies Financial Group raised their target price on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Barrington Research upped their price target on Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, January 30th. StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and boosted their price objective for the company from $69.00 to $84.00 in a research report on Monday, January 6th.

Insider Transactions at Henry Schein

In related news, COO Michael S. Ettinger sold 12,240 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the transaction, the chief operating officer now directly owns 87,706 shares in the company, valued at approximately $6,577,950. The trade was a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.14% of the company’s stock.

Institutional Trading of Henry Schein

A number of hedge funds have recently bought and sold shares of the business. Cromwell Holdings LLC boosted its holdings in shares of Henry Schein by 93.4% during the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after purchasing an additional 170 shares during the last quarter. Versant Capital Management Inc lifted its position in Henry Schein by 274.6% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $32,000 after buying an additional 335 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in Henry Schein by 3,347.1% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock worth $41,000 after buying an additional 569 shares during the last quarter. Quent Capital LLC boosted its stake in Henry Schein by 91.2% during the fourth quarter. Quent Capital LLC now owns 677 shares of the company’s stock worth $47,000 after buying an additional 323 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after buying an additional 143 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Price Performance

NASDAQ:HSIC opened at $77.48 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The company has a 50 day moving average price of $73.80 and a 200-day moving average price of $71.90. Henry Schein has a 1-year low of $63.67 and a 1-year high of $82.63. The firm has a market cap of $9.66 billion, a price-to-earnings ratio of 31.88, a price-to-earnings-growth ratio of 2.21 and a beta of 0.91.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.